Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
NCT01897441 · Albert Einstein College of Medicine · NA · terminated · last registry update 2024-12-24 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Interventional component of study terminated prior to full enrollment” | – | Registry record, Albert Einstein College of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-11Phase 3 first posted: Merck Sharp & Dohme LLC, Patritumab deruxtecan + Paclitaxel (NCT07060807)
- 2025-05-13Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06966700)
- 2024-06-12Results posted on the registry: ECOG-ACRIN Cancer Research Group, Docetaxel + Paclitaxel (NCT04001829)
- 2024-05-23Results posted on the registry: University of Arkansas, P10s-PADRE/ MONTANIDE™ ISA 51 VG + Doxorubicin (NCT02229084)
- 2024-03-15Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06312176)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision